Abbott Laboratories (ABT) Enterprise Value to EBITDA (EV/EBITDA): 23.53

Since December 31st, 2007, Abbott Laboratories's enterprise value to ebitda (ev/ebitda) has increased from 6.66 to 23.53 at June 1st, 2020.

From 2007 to 2020 Abbott Laboratories's highest enterprise value to ebitda (ev/ebitda) was 23.53
Abbott Laboratories's lowest enterprise value to ebitda (ev/ebitda) during that period was 3.90
Abbott Laboratories's average enterprise value to ebitda (ev/ebitda) from 2007 to 2020 Abbott Laboratories's was 12.19

Abbott Laboratories's enterprise value to ebitda (ev/ebitda) as of June 2nd, 2020 of 23.09 was lower than its peers in the Medical Appliances & Equipment industry group of May 31st, 2020 of 74.54. From December 31st, 2007 to June 2nd, 2020, Abbott Laboratories's average enterprise value to ebitda (ev/ebitda) was 12.26 compared to an industry average of 44.92.

About Abbott Laboratories

Abbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure and other medical device products. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.